首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Stereotactic fractionated irradiation of optic nerve sheath meningioma: a new treatment alternative
【2h】

Stereotactic fractionated irradiation of optic nerve sheath meningioma: a new treatment alternative

机译:立体定向分次照射视神经鞘膜脑瘤:一种新的治疗选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Primary optic nerve sheath meningioma (ONSM) is a rare but almost invariably blinding tumour when its natural history is observed in a “wait and see” strategy. Surgery has hitherto only been advocated in case of progressive disease involving intracranial structures, as it leads to iatrogenic blindness in the overwhelming majority of cases. Therefore, treatment options bearing lesser risk of functional deterioration are highly desirable, both in cases of intracranial involvement as well as during earlier phases of the disease which are currently generally left untreated. The authors report the outcome of the largest series of patients to date treated by stereotactic fractionated irradiation as a new treatment approach in ONSM at all stages.>Methods: 15 patients (16 nerves) underwent stereotactic fractionated conformal irradiation with a total dose of 54 Gy, using standard fractionation. Main outcome parameters included visual acuity and visual field, as well as three dimensional remission as documented by imaging.>Results: Tumour control was confirmed in all 15 patients undergoing stereotactic fractionated conformal irradiation (mean follow up 37 (range 12–71) months). No patient developed functional deterioration during or after treatment. Moreover, visual acuity improved by more than two lines in one patient and the visual field improved in six cases. Visual outcome in the other patients remained unchanged. There were no significant side effects of radiation therapy.>Conclusion: These data provide convincing evidence that stereotactic fractionated conformal irradiation is an effective treatment option for primary ONSM with minimal treatment related morbidity. It should therefore be considered as therapeutic option both in early stage ONSM where surgery cannot be justified as well as in later stages, where surgery is so far considered the first line approach.
机译:>背景:原发性视神经鞘膜脑膜瘤(ONSM)是一种罕见的肿瘤,但通过“等待与观察”策略观察其自然病史时,几乎总是盲目的。迄今为止,仅在涉及颅内结构的进行性疾病的情况下才提倡手术,因为它在绝大多数情况下导致医源性失明。因此,无论是在颅内受累的情况下,还是在疾病的早期阶段,目前都通常不予治疗,因此,功能变差风险较小的治疗选择是非常需要的。作者报告了迄今为止,通过立体定向分次放射治疗的最大系列患者的结果,作为ONSM在所有阶段的一种新治疗方法。>方法::15例患者(16条神经)接受了立体定向分形保形放射治疗使用标准分馏法,总剂量为54 Gy。主要结局参数包括视力和视野,以及影像学证实的三维缓解。>结果:在接受立体定向分形保形照射的所有15例患者中均确认了肿瘤控制(平均随访37(范围) 12–71)个月)。在治疗期间或之后,没有患者出现功能恶化。此外,一名患者的视力提高了两行以上,六例患者的视野得到了改善。其他患者的视觉结果保持不变。放射治疗没有明显的副作用。>结论:这些数据提供了令人信服的证据,表明立体定向分形保形放射是原发性ONSM的有效治疗选择,其发病率最低。因此,无论是在尚无合理手术理由的ONSM早期阶段,还是迄今仍被认为是一线手术的晚期阶段,均应将其视为治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号